HighLight Capital Terms and Conditions
  • Home
  • About
  • Team
  • Portfolio
  • News
  • Contact Us
HighLight Capital Terms and Conditions

Latest News

VelaVigo Announces Over $60 Million in Pre-A+ Financing
2025-07-29

VelaVigo Announces Over $60 Million in Pre-A+ Financing

to Accelerate Global Clinical Development of First-in-Class Drug Pipeline
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing
2025-07-10

NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing

to advance the clinical development of NUCLIDIUM's Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications
HLC Invests in Tawada Healthcare to Support Health System Strengthening in Indonesia
2025-05-29

HLC Invests in Tawada Healthcare to Support Health System Strengthening in Indonesia

Expand access to affordable, high-quality medical products and accelerate the transfer of essential healthcare technologies across Indonesia
Nuevocor Closes US$45 Million Series B Financing
2025-05-07

Nuevocor Closes US$45 Million Series B Financing

The new investment will be for clinical development of novel mechanobiology-centered therapy for cardiomyopathy
Healthcare focus drives HighLight Capital's exits amid market downturn
2025-02-24

Healthcare focus drives HighLight Capital's exits amid market downturn

The Shanghai-based private investment firm achieved significant exits via trade sales
ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11
2025-02-06

ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11

Demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimus
  • 1
  • 2
  • 3
  • 4
  • 5
  • 29 records in total
HighLight Capital Terms and Conditions
Home
About
Team
Portfolio
News
Contact Us
Copyright © 2014-2025 HighLight Capital Terms and Conditions. All Rights Reserved.